



CLAIMS

1. Compounds with general formula (I)



in which



$m$  is the number 0 or 1;

$Z$  and  $Z'$ , which can be the same or different, are an integer ranging from 0 to 2;

$Y$  and  $Y'$ , which can be the same or different, are  $(CH_2)_{n_1}$ ;  $(CH_2)_{n_2}-CH[NR^{VII}](CH_2)_{n_4}-NHR^I$ ;  $-(CH_2)_{n_3}$ ;  $CH_2-CH[CH_2-CH_2]_2-$  or  $(CH_2)_{n_2}-N[(CH_2)_{n_4}-NHR^{IV}](CH_2)_{n_3}$ ;

$Y''$  is selected from the group consisting of H; cycloalkyl  $C_3-C_7$ ;  $(CH_2)_{n_5}-N[CH_2-CH_2]_2N-(CH_2)_{n_6}-NHR^V$ ;  $(CH_2)_{n_7}-CH[CH_2-CH_2]_2NR^V$ ;

$X$  is O, or is a simple bond;

$n-n_8$ , which can be the same or different, are an integer ranging from 0 to 5;

$R^I$ ,  $R^{II}$ ,  $R^{III}$ ,  $R^{IV}$ , and  $R^V$ , which can be the same or different, are a protective group for the nitrogen to which they are bound;  $CO_2R^{VI}$ ;  $CO_2CH_2Ar$ ;  $CO_2(9\text{-fluorenylmethyl})$ ;  $(CH_2)_{n_5}-NHCO_2R^{VI}$ ;  $CH_2Ar$ ;  $COAr$ ;  $(CH_2)_{n_5}-NHCO_2CH_2Ar$ ;  $(CH_2)_{n_5}-NHCO_2(9\text{-fluorenylmethyl})$ .

R<sup>VI</sup> is a straight or branched (C<sub>1</sub>-C<sub>6</sub>) alkyl;

R<sup>VII</sup> is H or R<sup>I</sup>-R<sup>V</sup>;

Ar is a C<sub>6</sub>-C<sub>12</sub> aromatic residue, such as phenyl, optionally substituted with one or more groups selected from: halogen, hydroxy, C<sub>1</sub>-C<sub>5</sub> alkyl, C<sub>1</sub>-C<sub>5</sub> alkoxy, phenyl, cyano, nitro, -NR<sup>VIII</sup>R<sup>IX</sup>, where R<sup>VIII</sup> and R<sup>IX</sup>, which can be the same or different, are hydrogen, straight or branched (C<sub>1</sub>-C<sub>5</sub>) alkyl, or Ar is a heterocyclic group, said heterocyclic group containing at least one heteroatom selected from a nitrogen atom, optionally substituted with a (C<sub>1</sub>-C<sub>5</sub>) alkyl group, and/or oxygen and/or sulphur; said heterocycle can be substituted with one or more groups selected from halogen, hydroxy, C<sub>1</sub>-C<sub>5</sub> alkyl, C<sub>1</sub>-C<sub>5</sub> alkoxy, phenyl, cyano, nitro, -NR<sup>VIII</sup>R<sup>IX</sup>, where R<sup>VIII</sup> and R<sup>IX</sup>, which can be the same or different, are hydrogen, straight or branched (C<sub>1</sub>-C<sub>5</sub>) alkyl, the N<sub>1</sub>-oxides, racemic mixtures, their individual enantiomers, their individual diastereoisomers, the *E* and *Z* forms, their mixtures, and pharmaceutically acceptable salts.

2. Compounds according to claim 1, in which the protective groups are bulky groups of a lipophilic nature.

3. Compounds according to claim 1, in which the protective groups are selected from the group consisting of: CO<sub>2</sub>R<sup>VI</sup>; CO<sub>2</sub>CH<sub>2</sub>Ar; CO<sub>2</sub>-(9-fluorenylmethyl); (CH<sub>2</sub>)<sub>n5</sub>-NHCO<sub>2</sub>R<sup>VI</sup>; (CH<sub>2</sub>)<sub>n5</sub>-NHCO<sub>2</sub>CH<sub>2</sub>Ar; (CH<sub>2</sub>)<sub>n5</sub>-NHCO<sub>2</sub>-(9-fluorenylmethyl), in which R<sup>VI</sup> is as defined above.

4. Compounds according to claim 3, in which the protective groups are selected from the group consisting of tert-butoxycarbonyl; benzyloxycarbonyl; 9-fluorenylmethyloxycarbonyl.

5. Compounds according to any of claims 1-4, in which m is 0.

6. Compounds according to claim 5, selected from the group consisting of:

- tert-butylester of 20S-(4-{{3-(7-camptothecinylidene-amino)-propyl}-tert-butoxycarbonyl-amino}-butyl)-(3-tert-butoxycarbonylamino)propyl)-carbamic acid;
- tert-butylester of 20S-(4-{{3-(7-camptothecinylidene-amino)-propyl}-tert-butoxycarbonyl-amino}-butyl)-carbamic acid;
- tert-butylester of 20S-[3-(7-camptothecinylidene-amino)-butyl]-carbamic acid;
- 20S-7-[3-(N-tert-butoxycarbonylamino)propoxyimino-methyl]-camptothecin.

7. Compounds according to any of claims 1-4, in which m is 1.

8. Compounds according to claim 7, selected from the group consisting of:

- tert-butylester of 20RS-(4-{{3-(7-homocamptothecinylidene-amino)-propyl}-tert-butoxycarbonyl-amino}-butyl)-(3-tert-butoxycarbonylamino)propyl)-carbamic acid;
- tert-butylester of 20RS-(4-{{3-(7-homocamptothecinylidene-amino)-propyl}-tert-butoxycarbonyl-amino}-butyl)-carbamic acid;
- tert-butylester of 20RS-[3-(7-homocamptothecinylidene-amino)-butyl]-carbamic acid;
- 20R,S-7-[3-(N-tert-butoxycarbonylamino)propoxyimino-methyl]-homocamptothecin

9. Pharmaceutical composition containing at least one compound according to claims 1-8 as the active ingredient in admixture with at least one pharmaceutically acceptable vehicle and/or excipient.

10. Use of compounds according to claims 1-8 as medicaments.

11. Use of compounds according to claims 1-8 for the preparation of a medicament with topoisomerase 1 inhibiting activity.

12. Use according to claim 11 for the preparation of a medicament with anticancer activity.

13. Use according to claim 11 for the preparation of a medicament with antiparasite activity.

14. Use according to claim 11 for the preparation of a medicament with antiviral activity.